Selected Quarterly Financial Information

12 Months Ended

Dec. 31, 2011

Selected Quarterly Financial Information [Abstract]

Selected Quarterly Financial Information

SELECTED QUARTERLY FINANCIAL INFORMATION (UNAUDITED)

(in thousands, except per share data)

		First		Second		Third			Fourth
		Quarter		Quarter		Quarter			Quarter
REVENUE:
2011	$	30,196	$	29,379	$	29,654		$	30,397
2010		29,717		29,263		28,443			29,222
2009		26,688		28,163		28,219			28,615
GROSS MARGIN:
2011	$	18,504	$	19,053	$	18,912		$	19,375
2010		17,792		17,769		15,222	*		17,585
2009		17,235		17,895		17,041			17,597
NET INCOME (LOSS):
2011	$	1,666	$	1,820	$	2,019		$	1,866
2010		1,934		2,926		(3,031	)*		2,115
2009		1,949		2,502		1,862			2,366
INCOME (LOSS) PER COMMON SHARE—DILUTED:
2011	$	0.06	$	0.07	$	0.07		$	0.07
2010		0.07		0.10		(0.11	)*		0.08
2009		0.07		0.09		0.07			0.08

* The third quarter 2010 gross margin, net loss, and loss per share-diluted includes the unfavorable effect of a $1.6 million write-down of HemoStase inventory as a result of Medafor, Inc.'s termination of the distribution agreement between the parties. The third quarter 2010 net loss and loss per share-diluted also includes the unfavorable effects of $3.5 million in acquired in-process research and development expense, as a result of the transaction with Starch Medical, Inc., and $3.6 million for the other than temporary impairment of the Company's investment in Medafor common stock.